Deals this week: T2 Biosystems, Halt Medical, Berkeley Lights (BLI)

3 November 2016 (Last Updated November 3rd, 2016 18:30)

T2 Biosystems and Allergan have signed an agreement for the development of a novel bacterial resistance diagnostic panel that detects Gram-negative bacteria and antibiotic resistance in patients with serious bacterial infections.

T2 Biosystems and Allergan have signed an agreement for the development of a novel bacterial resistance diagnostic panel that detects Gram-negative bacteria and antibiotic resistance in patients with serious bacterial infections.

Pursuant to the agreement, Allergan will pay $4m in milestone payments for the development of the new panel and for expansion of another under-development T2Bacteria panel to T2 Biosystems, which retains exclusive worldwide rights to distribute all the products developed through the partnership.

Halt Medical has received an exclusive licence to use InnerOptic Technologies' FDA-cleared Aim 3D guidance software, which will be incorporated in Halt’s Acessa Guidance System, for use in uterine fibroid ablation procedure.

The Acessa Guidance system, which incorporates electromagnetic tracking technology and radiofrequency ablation, guides physicians in reaching the targeted fibroid by providing clear picture of the device trajectory and real-time tracking of the surgical instruments.

"The new company, in which, the former will own the majority stake of 51%, will be a healthcare technology company."

Diagnostic tests manufacturer, Guangzhou Wondfo Biotech, intends to form a joint venture (JV) with an individual in Guangzhou, China.

The new company, in which, the former will own the majority stake of 51%, will be a healthcare technology company.

With a vision to develop platforms that transform cell-based biological processes to accelerate the discovery, development and delivery of therapeutics, bio-technology firm Berkeley Lights (BLI) has partnered with Hoffman-LaRoche (Roche).

The two-year collaboration focuses on innovating and automating Roche's antibody discovery technology using BLI's opto-nanofluidic systems and devices and is anticipated to increase the efficiency and speed of novel therapeutics discovery.

Pharmaceutical test appliances and automated systems developer, Sotax AG, has received independent distribution rights to Waters Corporation’s Acquity UPLC H-Class System, which will be sold to drug manufacturers and pharmaceutical laboratories in the US, Canada, the UK, France, Germany, Italy, Switzerland and the Czech Republic.

The new collaboration combines the technologies of both the companies and enables their customers to efficiently streamline their analysis, characterisation and preparation of pharmaceutical samples thus helping them to improve their productivity and profitability.